Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.
Explore our resources designed to support Cosentyx initiation and ongoing maintenance for patients with plaque psoriasis.
You can download certain files below for you to share with your Cosentyx patients separately. Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.
Please note that these resources are designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.
Paediatric PsO Digital patient pack
This interactive PDF contains everything your paediatric PsO (6-17 years of age) patients need to get going with treatment and help them get the most out of it.
Adult PsO Digital patient pack
This interactive PDF contains everything your adult PsO patients need to get going with treatment and to help them get the most out of it.
300mg Patient alert leaflet
A short booklet containing information that your patients need to know in regards to the new UnoReady® 300mg injection pen.
Digital dosing schedule
An interactive PDF to help your newly initiated Cosentyx patients keep track of their treatment.
SensoReady® 150mg injection video
A short instructional video that demonstrates how to prepare and inject Cosentyx with the SensoReady® 150mg pen.
UnoReady® 300mg injection video
A short video showing you how to prepare and inject Cosentyx with the UnoReady® 300mg pen..
CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs.
